Meeting
2022 ASCO Annual Meeting
Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study.
Authors
Jifang Gong
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China
Jifang Gong , Lin Shen , Jie Hou , Xiaohua Chen , Qin Yu , Ying Zheng , Yakun Wang , Jian Zhang , Xiangdong Qu , Qiying Lu , Yejie Du , Qin Pan , Wencheng Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04856150
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2568)
DOI
10.1200/JCO.2022.40.16_suppl.2568
Abstract #
2568
Poster Bd #
223
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2022 ASCO Annual Meeting
A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
First Author: Toshio Shimizu
Poster
2022 ASCO Annual Meeting
Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.
First Author: Kelly C. Goldsmith